The Omalizumab Pharmacokinetic ELISA Kit is a state-of-the-art assay specifically developed for the quantitative analysis of omalizumab (Xolair) in biological matrices such as serum or plasma. This kit is critical for pharmacokinetic (PK) studies, therapeutic drug monitoring (TDM), and biosimilar research, enabling precise measurement of drug levels to optimize treatment and ensure compliance with therapeutic guidelines.
What is Omalizumab?
Omalizumab (Xolair) is a humanized monoclonal antibody designed to inhibit the binding of IgE to its receptor on mast cells and basophils, thereby preventing the release of inflammatory mediators. It is commonly prescribed for:
- Allergic asthma (moderate to severe cases).
- Chronic idiopathic urticaria.
- Other IgE-mediated diseases.
Applications of the ELISA Kit
- Pharmacokinetic Studies
- Measure and evaluate the absorption, distribution, metabolism, and excretion (ADME) of omalizumab.
- Generate concentration-time profiles for clinical studies.
- Therapeutic Drug Monitoring (TDM)
- Monitor patient-specific drug levels to optimize dosing.
- Ensure that plasma concentrations remain within therapeutic ranges to improve efficacy and reduce adverse effects.
- Biosimilar Development
- Compare pharmacokinetics of biosimilar candidates to Xolair.
- Detect and quantify differences in drug behavior and bioavailability.
- Clinical and Translational Research
- Investigate the relationship between omalizumab concentration and clinical outcomes.
- Evaluate drug levels in new therapeutic indications.
Key Features of the Omalizumab ELISA Kit
- High Sensitivity and Specificity
- Detects omalizumab concentrations as low as 10 ng/mL.
- Minimal cross-reactivity with other therapeutic monoclonal antibodies.
- Ready-to-Use Reagents
- Pre-coated plates, standards, and detection reagents streamline the workflow.
- Wide Sample Compatibility
- Suitable for human serum, plasma, and other validated biological matrices.
- Comprehensive Protocol
- Includes a step-by-step guide for reliable and reproducible results.
Technical Specifications
| Parameter | Details |
|---|---|
| Detection Range | 10–1000 ng/mL |
| Assay Sensitivity | ~10 ng/mL |
| Sample Volume | 50 µL per well |
| Assay Time | ~3 hours |
| Storage Conditions | 2–8°C |
| Cross-Reactivity | <1% with IgG or IgE |
Procedure Overview
- Sample Preparation
- Dilute samples according to the kit’s instructions.
- Load samples, standards, and controls into the wells.
- Incubation
- Incubate the plate with a specific anti-omalizumab detection antibody.
- Wash thoroughly to remove unbound substances.
- Signal Development
- Add substrate solution and measure optical density (OD) using a microplate reader at the specified wavelength.
- Data Analysis
- Generate a standard curve to quantify omalizumab concentration in the test samples.
Advantages of the ELISA Kit
- Accurate and Reliable
- High precision across replicates ensures reproducible results.
- User-Friendly
- Ready-to-use reagents simplify the workflow, making the assay accessible to a wide range of laboratories.
- Regulatory Compliance
- Versatility
- Can be adapted for high-throughput screening and various research applications.
Applications in Therapeutic Drug Monitoring (TDM)
Why Monitor Omalizumab Levels?
- Ensure Efficacy: Subtherapeutic levels may reduce drug effectiveness.
- Prevent Toxicity: Overexposure could lead to adverse effects.
- Personalized Therapy: Adjust dosages based on individual pharmacokinetics.
Clinical Use Case:
Research studies have demonstrated a correlation between omalizumab levels and the resolution of symptoms in allergic asthma. Monitoring levels using this ELISA kit can help achieve optimal clinical outcomes.
Applications in Biosimilar Research
- Comparative Pharmacokinetics
- This kit supports equivalence studies for regulatory approval of omalizumab biosimilars.
- Detects differences in bioavailability and immunogenicity.
- Batch Consistency Testing
- Ensures lot-to-lot consistency during biosimilar production.
Regulatory and Scientific Support
- FDA Guidance: The kit is developed in compliance with FDA bioanalytical validation guidelines (FDA Bioanalytical Method Validation).
- WHO Standards: Aligns with global pharmacokinetic study requirements (WHO).
Conclusion
The Omalizumab (Xolair) Pharmacokinetic ELISA Kit is an essential tool for researchers and clinicians working on IgE-mediated diseases and monoclonal antibody therapies. Its versatility, precision, and user-friendly design make it ideal for pharmacokinetic studies, therapeutic drug monitoring, and biosimilar development.
For more information, visit trusted resources like the NIH, FDA, and EMA. Let us know if you need further details or customized applications!








